Pharming Group

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming’s technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company’s commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.

Company Growth (employees)
Type
Public
HQ
Leiden, NL
Founded
1988
Size (employees)
94 (est)+19%
Pharming Group was founded in 1988 and is headquartered in Leiden, NL

Pharming Group Office Locations

Pharming Group has an office in Leiden
Leiden, NL (HQ)
24 Darwinweg

Pharming Group Financials and Metrics

Pharming Group Financials

EUR

Market capitalization (10-Oct-2017)

396.9 m

Closing share price (10-Oct-2017)

0.8
Pharming Group's current market capitalization is €396.9 m.
Show all financial metrics

Pharming Group Market Value History

Pharming Group's Web-traffic and Trends

Pharming Group Company Life and Culture

You may also be interested in